Seeking Alpha

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary ...
Nasdaq

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with ...

MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
Seeking Alpha

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional ...
Business Wire

TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
Nasdaq

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic ...
Business Wire

ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in ...
Business Insider

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late ...

New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection ...
Morningstar

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in ...
Monthly Prescribing Reference

FDA to Review Dry Powder Inhalation Formulation of Tyvaso

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the New ...
Labroots

Advancing Non-Invasive Peptide Delivery: Lessons from GLP-1 Inhalable Semaglutide Development

Glucagon-like peptide 1 (GLP 1) analogues enhance insulin secretion, delay gastric emptying, and promote satiety, making them effective therapeutics for type 2 diabetes and obesity [1],[2]. Structural ...
Business Insider

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated ...

FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act Final ...